Departments of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Departments of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Pract Radiat Oncol. 2022 Sep-Oct;12(5):e376-e381. doi: 10.1016/j.prro.2022.01.002. Epub 2022 Feb 1.
Cardiac radiation exposure is associated with an increased rate of adverse cardiac events in patients receiving radiation therapy for locally advanced non-small cell lung carcinoma (NSCLC). Previous analysis of practice patterns within the Michigan Radiation Oncology Quality Consortium (MROQC) revealed 1 in 4 patients received a mean heart dose >20 Gy and significant heterogeneity existed among treatment centers in using cardiac dose constraints. The purpose of this study is to analyze the effect of education and initiation of standardized cardiac dose constraints on heart dose across a statewide consortium.
From 2012 to 2020, 1681 patients from 27 academic and community centers who received radiation therapy for locally advanced NSCLC were included in this analysis. Dosimetric endpoints including mean heart dose (MHD), mean lung dose, and mean esophagus dose were calculated using data from dose-volume histograms. These dose metrics were grouped by year of treatment initiation for all patients. Education regarding data for cardiac dose constraints first occurred in small lung cancer working group meetings and then consortium-wide starting in 2016. In 2018, a quality metric requiring mean heart dose <20 Gy while maintaining dose coverage (D95) to the target was implemented. Dose metrics were compared before (2012-2016) versus after (2017-2020) initiation of interventions targeting cardiac constraints. Statistical analysis was performed using the Wilcoxon rank sum test.
After education and implementation of the heart dose performance metric, mean MHD declined from an average of 12.2 Gy preintervention to 10.4 Gy postintervention (P < .0001), and the percentage of patients receiving MHD >20 Gy was reduced from 21.1% to 10.3% (P < .0001). Mean lung dose and mean esophagus dose did not increase, and target coverage remained unchanged.
Education and implementation of a standardized cardiac dose quality measure across a statewide consortium was associated with a reduction of mean heart dose in patients receiving radiation therapy for locally advanced NSCLC. These dose reductions were achieved without sacrificing target coverage, increasing mean lung dose, or increasing mean esophagus dose. Analysis of the clinical ramifications of the reduction in cardiac doses is ongoing.
心脏辐射暴露与接受局部晚期非小细胞肺癌(NSCLC)放射治疗的患者不良心脏事件发生率增加有关。密歇根放射肿瘤学质量联盟(MROQC)之前对实践模式的分析显示,每 4 名患者中就有 1 名接受的平均心脏剂量>20Gy,并且在使用心脏剂量限制方面,各治疗中心之间存在显著的异质性。本研究的目的是分析在全州范围内的联盟中,通过教育和启动标准化心脏剂量限制对心脏剂量的影响。
2012 年至 2020 年,共纳入 27 个学术和社区中心的 1681 名接受局部晚期 NSCLC 放射治疗的患者进行了这项分析。使用剂量-体积直方图中的数据计算平均心脏剂量(MHD)、平均肺剂量和平均食管剂量等剂量学终点。将这些剂量指标按所有患者的治疗起始年份进行分组。关于心脏剂量限制数据的教育首先在小型肺癌工作组会议上进行,然后从 2016 年开始在联盟范围内进行。2018 年,实施了一项质量指标,要求平均心脏剂量<20Gy,同时保持靶区的剂量覆盖率(D95)。在针对心脏限制的干预措施开始之前(2012-2016 年)与之后(2017-2020 年)比较剂量指标。使用 Wilcoxon 秩和检验进行统计学分析。
在进行心脏剂量性能指标的教育和实施后,平均 MHD 从干预前的 12.2Gy 降至干预后的 10.4Gy(P<0.0001),接受 MHD>20Gy 的患者比例从 21.1%降至 10.3%(P<0.0001)。平均肺剂量和平均食管剂量没有增加,靶区覆盖率保持不变。
在全州范围内的联盟中,通过教育和实施标准化的心脏剂量质量指标,与局部晚期 NSCLC 接受放射治疗的患者的平均心脏剂量降低有关。这些剂量的降低是在不牺牲靶区覆盖率、增加平均肺剂量或增加平均食管剂量的情况下实现的。正在分析心脏剂量降低的临床影响。